Skip Navigation

Continuing Education in Anaesthesia, Critical Care & Pain 2004 4(6):210-212; doi:10.1093/bjaceaccp/mkh057
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Continuing Education in Anaesthesia, Critical Care & Pain | Volume 4 Number 6 2004 © The Board of Management and Trustees of the British Journal of Anaesthesia 2004

Multiple Choice Answers

The first 150 words of the full text of this article appear below.

128. Glycoprotein IIb/IIIa inhibitors:
(a) True; (b) False; (c) True; (d) False; (e) False
(a) GP IIb/IIIa inhibitors block fibrinogen cross-links between platelets. (b,c) They are not licensed with thrombolysis but have a role in stenting during PTCA. (e) There is no specific reversal therapy available.
129. The troponins:
(a) True; (b) True; (c) False; (d) False; (e) True
(a) Elevated serum troponins may reflect an area of myocardial necrosis weighing <1.0 g. (b) Troponins may remain elevated for up to 10 days. (c) This may reflect incomplete apoptosis as part of a non-ischaemic inflammatory process (e.g. in sepsis). (d) Typically detected at 4–10 h. (e) High TnT is associated with increased mortality in sepsis.
130. Regarding reperfusion therapy:
(a) False; (b) True; (c) False; (d) True; (e) False
(a) rt-PA is associated with an increased risk of bleeding. (b) Most benefit occurs in first 12 h. (c) PTCA is . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?